Goldman Sachs initiates coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $93.00.Analyst Gary ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE